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Abstract 
 
Background: Endoscopic management of nonvariceal upper gastrointestinal bleed (NVUGIB) 
can be challenging. Hemospray (Cook Medical, Winston-Salem, NC, USA is a novel endoscopic 
hemostatic agent for NVUGIB. Its efficacy in attaining hemostasis in NVUGIB is promising, 
particularly with respect to technically difficult lesions. However, most of the currently available 
data are focused on its application as monotherapy. The aim of this study was to evaluate its 
efficacy as a second agent to adrenaline, or as an addition to the combination of adrenaline with 
either clips or a thermal device in NVUGIB.  
 
Methods: Consecutive patients with Forrest 1a and 1b ulcer treated with hemostatic spray as an 
adjunct to conventional endoscopic hemostatic measures between July 2013 and June 2015 were 
included in this retrospective analysis. The endpoints were initial hemostasis, 7-day rebleeding, 
30-day rebleeding, all cause, and GI-related 30-day mortality.  
 
Results: A total of 20 (median age 75 years, 50% men, 60% Forrest 1a ulcer) were treated with 
hemostatic spray as a second agent to adrenaline, or as an adjunct to the combination of 
adrenaline with either clips or a thermal device. Hemostatic spray was used as a second agent to 
adrenaline in 40% and as a third agent to combined dual therapy in 60%. Initial hemostasis was 
attained in 95% with an overall rebleeding rate at 7-day of 16%. There was no difference between 
7-day and 30-day rebleeding rate. The combination of hemostatic spray and adrenaline resulted in 
100% initial hemostasis and 25% 7-day rebleeding. Similarly, initial hemostasis was achieved in 
92% with 9% rebleeding rate when hemostatic spray was used as the third agent to 2 of the 
conventional measures. All-cause mortality was 15% with one GI-related death (3%).  
 
Conclusion: In our single-center retrospective analysis, hemostatic spray appears promising as an 
adjunct to conventional methods for NVUGIB, although prospective controlled trials are needed 
to confirm. 
 
 
Keywords:  
Hemospray, nonvariceal gastrointestinal bleeding, hemostatic powder 
 
 
 
 
Introduction 
 
Mortality associated with acute upper gastrointestinal bleeding remains high at 10% 1, 2. This 
figure has not changed appreciably since the 1950s in part due to an aging population. In a recent 
United Kingdom-wide audit, 1 in 4 patients with acute upper GI bleeding were aged over 80 
years 2. Because mortality from upper GI bleeding increases steeply with age, peptic ulcer 
bleeding will continue to pose a significant therapeutic challenge 3. Recent advances in 
endoscopic techniques have enabled effective hemostatic interventions to be deployed. The 
combination of adrenaline with a mechanical method (clips) or with a thermal device is the 
preferred strategy to achieve hemostasis 4-6. Indeed, monotherapy with adrenaline has largely 
been superseded by this approach due to an unacceptably high rate of rebleeding 7. However, in 
10% to 20% of patients, rebleeding occurs despite initial hemostasis with combined therapy 1.  
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Hemostatic sprays are relatively new addition to the established hemostatic agents. Hemospray 
(Cook Medical, Winston-Salem, NC, USA is the first to be licensed in Europe, but it is not as yet 
FDA approved. It is a proprietary inorganic hemostatic powder approved for use in nonvariceal 
upper gastrointestinal bleed (NVUGIB). The powder is propelled through a carbon dioxide 
pressurized catheter fed through the working channel of an endoscope and sprayed at a distance 
of 1 to 2 cm from the bleeding site until a complete coating of the lesion and an obliteration of 
fresh blood is achieved. When put in contact with moisture (eg, blood or tissue) in the GI tract, 
the powder becomes cohesive and adhesive8. Its hemostatic mechanisms are 2-fold. First, it 
exerts a tamponade effect by forming a confluent mechanical barrier at the bleeding site. Second, 
it promotes thrombus formation by enhancing platelet aggregation and increasing the 
concentration of clotting factors 9. Additionally, it has been shown to shorten coagulation time in 
vitro 10.  
 
The effect of hemostatic spray on hemostasis in NVUGIB cases so far has been encouraging. 
Initial hemostasis was achieved in 81% to 100% with rebleeding rate of 5-39% 11-15. However, 
most of these data were focused on the use of Hemospray as monotherapy. Moreover, the study 
populations are heterogeneous with respect to the underlying etiology. Data on the use of 
hemostatic spray as a second-line hemostatic agent to adrenaline or as an adjunct to combined 
therapy are limited. Intuitively, these strategies could offer a significant advantage; hemostatic 
spray may augment hemostasis achieved by standard therapy. This approach is attractive in cases 
in which the application of dual therapy is challenging. Adrenaline injection occasionally masks 
the bleeding lesion. More frequently, position of the ulcer renders the effective application of 
clips or heater probe impossible. Finally, the fibrous nature of the ulcer base or large size of a 
visible vessel may mean that attempting to apply clips or heater probe would be unlikely to 
succeed or potentially dangerous. 
 
In this study, we evaluated the effect of this hemostatic spray on initial hemostasis, rebleeding 
rate, and mortality when used in in high-risk patients with peptic ulcer bleed. Here, hemostatic 
spray was used as a second agent to adrenaline, or as an adjunct to the combination of adrenaline 
with either clips or a thermal contact device.  
 
 
Methods 
 
Study population 
This retrospective analysis reviewed 30 consecutive patients who had been treated with 
hemostatic spray for GI bleeding between July 1, 2013 and June 30, 2015 in a large tertiary unit. 
One case of hemostatic spray application to lower GI bleeding, one case with incomplete clinical 
information and 4 cases with the following underlying causes: gastroesophageal carcinoma, 
Mallory Weiss tear without visible vessel, angiodysplasia, and pangastritis, were excluded. Four 
patients with Forrest 2a and 2b ulcers were excluded due to the small sample size.   
 
The final analysis included the remaining 20 cases of Forrest 1a and 1b ulcers. Of these, one 
patient had post-ampullectomy GI bleeding, but a spurting arterial vessel was identified on the 
index gastroscopy. Similarly, another patient who had a Mallory Weiss tear was included in this 
group because a visible vessel was treated. The nature of the lesions in these 2 cases was akin to 
that of a peptic ulcer and therefore were considered as Forrest 1a and 1b, respectively. In these 
cases, hemostatic spray was used either as a second agent to adrenaline or as an adjunct to the 
combination of adrenaline with either clips or a thermal contact device.  
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The outcomes were as follows: initial hemostasis (defined as adequate hemostasis confirmed on 
observation and to the satisfaction of endoscopist), 7-day and 30-day rebleeding (defined as (1) 
clinical presentation of hematemesis or melaena; (2) hemodynamic instability; (3) drop in 
hemoglobin ≥2 g/L, blood transfusion of ≥4 units; necessitating further investigation such as 
repeat endoscopy or radiological intervention); all cause and GI bleed-related 30-day mortality; 
adverse event; and equipment failure relating to the use of hemostatic spray 12. 
 
For comparison, we reviewed the outcomes of 20 consecutive patients with Forrest 1a and 1b 
ulcer who received conventional treatment before the introduction of hemostatic spray in our 
department between August 2010 and June 2013.  
 
Patients were identified using the endoscopy logbook entries. Endoscopy report and clinical 
information were obtained from Unisoft (Unisoft Medical Systems, Enfield, UK) and Trakcare 
(Intersystem Corporation, Cambridge, Mass) respectively. Demographics, Rockall, and 
Blatchford scores, antiplatelet use, findings at endoscopy, endoscopic therapeutic interventions, 
use of proton pump inhibitor infusions, Helicobacter pylori status, and the study end points were 
recorded. All identifiable data were replaced with study identification numbers to preserve 
confidentiality. The use of these data was approved by the Confidentiality (Caldicott) Guardian 
for NHS Lothian. 
 
This study was considered as a retrospective review by the local committee in our institution; 
hence, no formal ethical approval from the NHS Research Ethics Committee was necessary.  
 
 
Clinical procedure 
The choice of treatment was at the discretion of the attending endoscopist. All patients were 
adequately resuscitated before the endoscopic procedure. Hemostatic spray was used to achieve 
complete hemostasis if there was evidence of continued oozing after conventional therapy 
(adrenaline with either hemostatic clips or thermal devices). Similarly, hemostatic spray was used 
after adrenaline injection if the lesion was inaccessible for application of hemostatic clips or 
thermal devices. Hemostatic spray was delivered through a 10F catheter (Cook Medical, 
Winston-Salem, NC, USA) fed through the working channel of an endoscope (Olympus, Japan 
or FujiFilm, Japan). Adequacy of hemostasis was confirmed on observation of the treated lesion 
and to the satisfaction of the endoscopist. All patients received intravenous proton pump 
inhibitor infusion for 72 hours (Hong Kong regimen) after endoscopy.  
 
 
Statistical analysis 
Statistical analysis was performed using IBM SPSS for Macintosh version 22.0 (IBM 
Corporation, Armonk, NY, USA). Mann-Whitney U test was used to compare continuous 
variables between two populations. The Fisher exact test was used to compare categorical 
variables between 2 groups. Data are presented in median interquartile range (IQR) or frequency 
(percentage of the total study population). A 2-sided P value of less than .05 was considered to be 
statistically significant.  
 
Results 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
Hemostatic spray group 
A total 20 patients (median age 75 (IQR=11) years, men 50%) were included in the final analysis. 
Of these, 60% (12/20) had Forrest 1a and 40% (8/20) had Forrest 1b. The median Rockall score 
and Blatchford score were 8 (IQR = 2) and 14 (IQR = 6) respectively. Ten (50%) patients were 
on anti-platelet agents at the time of presentation. 
 
Hemostatic spray was used as a second agent to adrenaline (AH) in 8 (40%) and as an addition to 
combined therapy (DH) in 12 (60%) patients (Table 1). The reasons for hemostatic spray 
application in the AH group were as follows: lesions in difficult site, suboptimal views, and 
concerns regarding perforation or torrential hemorrhage, all of which had precluded effective 
deployment of hemostatic clips or a thermal contact device.  Hemostatic spray was used as a 
third agent with persistent oozing or in cases where the risk of rebleeding remained significant 
despite the conventional dual therapy. Descriptions of individual cases are provided in 
Supplementary Table 1. 
 
Initial hemostasis and rebleeding 
Initial hemostasis was achieved in 19 out of 20 (95%) cases. One patient (5%) who did not 
achieve initial hemostasis despite the use of hemostatic spray in the DH group subsequently had 
gastroduodenal artery embolization to achieve hemostasis. Seven-day rebleeding occurred in 16% 
(3/19; median day 0, IQR = 3). Rebleeding events in the AH and DH group were 25% (2/8) and 
9% (1/11), respectively (Table 3). Two of the rebleeding cases were treated with gastroduodenal 
artery embolization. One patient was too frail for further intervention and subsequently died. 
There was no rebleeding recorded beyond day 7. Thus, the 30-day rebleeding remained at 15%. 
 
Mortality 
All-cause mortality at 30 days in the hemostatic spray group was 15% (3/20) (Table 3). GI bleed-
related mortality at 30-day was 5% (1/20). Other causes of death were septicemia and aspiration 
pneumonia.  
 
Rebleeding event and mortality according to the severity of bleed 
Forrest 1a 
Forty-two percent (5/12) of those with Forrest 1a lesions received hemostatic spray as a second 
line to adrenaline therapy (AH) (Table 3). In this group, initial hemostasis was achieved in 100%. 
However, rebleeding was noted in 40% (2/5). The 30-day mortality in this group was 20% (1/5). 
The remaining 58% (7/12) had hemostatic spray in conjunction with the combined therapy 
(DH). Of these, the initial hemostasis rate was 86% (6/7). Rebleeding occurred in 17% (1/6). 
There was no mortality in this group. 
 
Forrest 1b 
Thirty-eight percent (3/8) of patients with Forrest 1b lesions had AH therapy, with initial 
hemostasis of 100%, 0% rebleeding, and 0% 30-day mortality (Table 3). The remaining 62% 
(5/8) received DH therapy. Initial hemostasis was 100%, and there were no rebleeding episodes. 
However, 30-day mortality was 40% (2/5). One death was due to septicemia and another was 
due to aspiration pneumonia. 
 
Other adverse events and technical failure with hemostatic spray 
There was no significant hemostatic spray-related equipment failure. On occasion, it was 
necessary to use the second supplied catheter to achieve adequate therapy. This was due to 
blockage within the first catheter induced by moisture within the endoscope channel or the gut 
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lumen. The former can be minimized by vigorous flushing of the endoscope channel with air 
before catheter insertion. No other adverse event was observed. 
 
 
Conventional therapy group outcomes (August 2010 to June 2013) 
 
Baseline characteristics (age, gender, etiology, preceding anti-thrombotic use, Rockall and 
Blatchford scores) were similar in both groups (Table 2). Descriptions of individual cases are 
provided in Supplementary Table 2. 
 
Initial hemostasis and rebleeding 
Initial hemostasis with conventional strategies was achieved in 16 out of 20 (80%) and rebleeding 
occurred in 4 out of 16 (25%) and 5 out of 16 (31%) at 7 days and 30 days, respectively. Three 
out of 4 patients with failed initial hemostasis required emergency laparotomy. One died of 
ongoing bleeding. Three patients were treated with adrenaline monotherapy due to technical 
difficulties in deploying clips or thermal device. Rebleeding occurred in 2 out of 3 (67%) of these 
cases. Among those who received the standard dual therapy (adrenaline and hemostatic clips 
(AC) or adrenaline and a thermal device (AT), initial hemostasis was achieved in 14 out of 17 
(82%). The 30-day rebleeding rate of 21% (3/14) was comparatively higher than that seen with 
the combination of hemostatic spray and standard dual therapy (9%).  
 
Mortality 
The overall 30-day mortality with conventional therapy was 6 out of 20 (30%), and GI bleed-
related death occurred in 3 out of 20 (15%).  
 
Discussion 
 
Our study examined the efficacy of Hemospray as a second agent to adrenaline and as a third 
agent to the combined therapy in high-risk patients with nonvariceal upper GI bleed. These 
patients were truly high risk with median Rockall and Blatchford scores of 8 and 14, respectively. 
In this context, our rationale was to use hemostatic spray to maximizethe hemostatic effect. Our 
data highlight 2 important points. First, using this approach, hemostatic spray was effective in 
attaining initial hemostasis as evident by the favorable rate of 95%. Second, hemostatic spray 
offers a good protection against rebleeding. Indeed, the overall rebleeding rate in our cohort was 
16%, and when used in combination dual conventional treatment modalities, the rebleeding rate 
was a mere 9%. 
 
In this study, hemostatic spray was used as a second agent to adrenaline in 40% of cases in which 
the deployment of clips or thermal contact devices was not technically feasible. Initial hemostasis 
achieved in combination with adrenaline was 100%, even in high-risk lesions. Importantly, the 
rebleeding rate of 25% in Forrest 1a and Forrest 1b ulcers with this combination was better than 
that seen with adrenaline monotherapy for similar lesions 16, 17. When compared with our 
previous experience in a group of patients with Forrest 1a and 1b lesions before introduction of 
hemostatic spray in our unit, rebleeding occurred in 67% when the therapeutic option was 
technically limited to adrenaline monotherapy. Therefore, hemostatic spray may be a viable 
alternative for lesions inaccessible to hemostatic methods which require precise targeting. To this 
end, hemostatic spray can be applied without direct mucosal contact or en face view of a lesion. 
Prior injection of adrenaline can provide an immediate clear visualization for a targeted 
application of hemostatic spray and complement its hemostatic effect. Thus, hemostatic spray 
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offers ease of application, particularly in technically challenging cases. It obviates the need for 
more advanced techniques such as the use of a duodenoscope or a cap-assisted approach, for 
which the required skills may not be widely available. 
 
Sustained hemostasis with a combination of hemostatic spray and adrenaline in our cohort was 
comparatively lower than that reported with conventional measures, particularly for Forrest 1a 
ulcers 18-22. It is of interest that although Hemospray has been licensed as monotherapy for 
NVUGIB, its efficacy in Forrest 1a lesions has not been adequately studied. Our center 
experience of hemostatic spray as monotherapy was limited to a single case where it was 
successfully used to control a significant bleeding episode from pangastritis. In a porcine model, 
hemostatic spray induces 100% hemostasis with 20% rebleeding within 24 hours 19. These 
findings were corroborated by subsequent clinical studies. For example, Sung et al12 achieved 
95% initial hemostasis with 85% sustained hemostasis at 72 hours in patients with Forrest 1a and 
1b ulcers. Likewise, Smith et al11 reported initial hemostasis in 85% and a rebleeding rate of 15% 
using hemostatic spray as  monotherapy. However, in a subsequent case series, the rate of 
rebleeding with hemostatic spray  monotherapy was considerable prompting authors to 
recommend either a second re-look or prolonged hospital observation 23. This raises the question 
as to whether hemostatic spray as monotherapy is a cost-effective approach. This was addressed 
in a recent study, which showed that the combination of hemostatic spray with conventional 
hemostatic measures was more cost-effective than hemostatic spray as monotherapy 24. In a 
recent case series, the use of hemostatic spray as monotherapy in Forrest 1a lesions was 
associated with 100% rebleeding necessitating further endotherapy or interventional radiology 25. 
Therefore, the available evidence currently suggests that hemostatic spray monotherapy is 
unlikely to replace conventional hemostatic therapy. 
 
In our series, hemostatic spray was used as an adjunct to the standard dual therapy in cases where 
the risk of rebleeding was deemed to be significant. This triple therapy approach resulted in the 
overall initial hemostasis of 92% with the rebleeding rate of 9%. Even among those with Forrest 
1a, the initial hemostasis and the rebleeding rate were encouraging. Furthermore, in Forrest 1a 
and 1b lesions, the rebleeding rate of 9% was comparatively less than the rebleeding rate reported 
with the conventional approaches for similar lesions 13, 17, 26. Indeed, the hemostatic effect with 
the triple therapy surpassed the initial hemostasis of 82% and the rebleeding rate of 21% 
previously observed with the conventional dual therapy in our institution. This effect might be 
explained by the ability of hemostatic spray to cover large areas and address multiple bleeding 
points from feeding vessels simultaneously. It could be surmised that the spray provides a sealant 
barrier that complements tamponade, vasoconstriction, and mechanical or thermal coagulation 
resulting from conventional combination therapy. 
 
Similar to the findings of a recent United Kingdom–wide audit, our cohort was elderly with 
median age of 75 years and the mortality observed was largely related to decompensation of 
comorbid conditions 2. One GI bleed-related death was attributable to a duodenal ulcer that had 
rebled. In this case, no further intervention was deemed appropriate due to significant frailty. In 
our study, there was no difference in mortality when hemostatic spray was used as an adjunct to 
adrenaline or incorporated into the standard combination therapy. Even though there have been 
reports of perforated viscus, biliary orifice obstruction, and splenic infarct associated with the use 
of hemostatic spray, we did not observe any adverse events in our cohort 14, 27. 
 
This study has several limitations. The retrospective nature precludes a comparison of the 
efficacy of hemostatic spray as monotherapy compared with its adjuvant use to dual therapy. 
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Cases were highly selected and treatment was at the discretion of the endoscopist rather than 
directed by a specific protocol. Data regarding the exact amount of hemostatic spray applied are 
unavailable. Our case series, albeit small, is the largest to date that reports the complementary 
role of hemostatic spray, either as a second agent after adrenaline injection or as a third agent 
after conventional dual therapy in high-risk nonvariceal upper GI bleeding.  
 
In conclusion, our data support the use of hemostatic spray in high-risk peptic ulcer bleeding, 
particularly when the application of additional hemostatic agents after adrenaline injection may 
not be technically feasible. Its use as an adjunct can be considered when primary hemostasis is 
not achieved with standard combination therapy. Whether it can replace conventional measures 
remains to be seen and its role in additionally securing hemostasis in high-risk patients remains 
unclear. Future prospective randomized controlled trials comparing hemostatic spray alone and 
in various combinations with conventional therapies in high-risk bleeding lesions are required to 
establish its optimal place in the hemostatic armamentarium. 
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Legends 
Figure 1: Forrest 1a duodenal ulcer 
 
Figure 2: Forrest 1a duodenal ulcer after a triple therapy (a combination of adrenaline, thermal 
device and hemostatic spray) 
 
Video Legend 
A 76-year-old woman with cardio-respiratory comorbidity had presented with major peptic ulcer 
bleeding 2 weeks previously. She remained in intensive care after a laparotomy and under-
running of a duodenal ulcer after failure of endoscopic hemostasis.  After further bleeding and 
cardiovascular instability developed, gastroscopy under general anesthetic was performed. The 
surgical team felt she would not survive a second laparotomy. 
 
The site of bleeding was a visible vessel in a high lesser curve gastric ulcer previously obscured by 
fundal clot. Circumferential adrenaline injection was performed to a total of 28 mL. The needle 
can be seen to puncture the feeding vessel during circumferential injection. The heater probe was 
used at 30J power setting to cavitate around the visible vessel. It was decided not to treat the 
vessel directly due to the high risk of precipitating torrential hemorrhage. The vessel began to 
actively ooze during therapy. Clips would not have been an option due to the chronic fibrous 
ulcer base. Therefore, hemostatic spray was used to effect hemostasis. The patient underwent a 
semi-urgent left gastric artery embolization the following day and was successfully discharged 
home 2 months later.  
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*Others:  Mallory Weiss with visible vessel, ampullectomy with arterial spurt.  
Data presented as median (IQR) or n. 
 
Table 1: Demographics and clinical characteristics of patients treated with hemostatic 
spray. 
Clinical characteristics Adrenaline + hemostatic 
spray  (AH) 
n=8 
Dual therapy + hemostatic 
spray (DH)  
n=12 
P value 
Age (years) 75 71 0.73 
Women 3 7 0.65 
Rockall score 8 8 0.75 
Blatchford score 14 15 0.51 
Use of 
antithrombotic therapy 
5 5 0.64 
 
Pathology 
Duodenal ulcer 
Esophageal ulcer 
Dual pathology 
Gastric ulcer 
Others* 
 
 
4 
3 
0 
0 
1 
 
 
8 
1 
1 
1 
1 
 
0.65 
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Clinical characteristics  
Hemostatic spray group 
(July 2013- August 2015) 
n=20  
Conventional therapy 
(August 2010 – June 2013) 
n=20 
 
P 
value 
Age (years)  75 (11) 73 (21) 0.72 
Women 10 9 1.00 
Rockall score  8 (2) 7 (3) 0.30 
Blatchford score 14 (6) 14 (4) 0.82 
Use of antithrombotic therapy 10 12 0.75 
Data presented as median (IQR) or n. 
 
Table 2: Clinical characteristics of patients with Forrest 1a and 1b ulcers in hemostatic 
spray and conventional therapy 
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AH, adrenaline plus hemostatic spray; DH, conventional dual therapy plus hemostatic spray; A, adrenaline alone; D, conventional 
dual therapy (a combination of adrenaline with hemostatic clips or a thermal device); * 30-day rebleeding. 
 
Table 3: Initial hemostasis, rebleeding events, and 30-day mortality stratified according to the 
Forrest classification in hemostatic spray and conventional treatment groups 
 
 
 
 
 
 
Forrest 
classificati
on 
 
Hemostatic spray treatment 
(July 2013 – August 2015) 
 
Conventional treatment  
(August 2010 – June 2013) 
 
 
Risk of  
rebleedi
ng after 
endosco
pic 
treatmen
t 28 in 
literature 
Study population 
n (%) 
Initial 
hemosta
sis 
n (%) 
7-day 
rebleedi
ng 
n (%) 
Mortali
ty 
30-day 
n (%) 
Study 
populatio
n 
n (%) 
Initial 
hemosta
sis 
n (%) 
7-day 
rebleedi
ng 
n (%) 
Mortali
ty 
30-day 
n (%) 
 
 
 
1a 
 
 
 
12 (60) 
 
AH 
 
 
5 (42) 
 
5 (100) 
 
2 (40) 
 
1 (20) 
 
A 
 
 
0 (0) 
 
0 (0) 
 
- 
 
 
0 (0) 
 
 
 
0-69% 
13, 29, 30 
 
 
DH 
 
 
7 (58) 
 
6 (86) 
 
1 (17) 
 
0 (0) 
 
 
D 
 
 
12 
(100) 
 
9 (75) 
 
1 (11) 
2* (22) 
 
 
2 (22) 
 
 
 
1b 
 
 
 
8 (40) 
 
AH  
 
 
3 (38) 
 
3 (100) 
 
0 (0) 
 
0 (0) 
 
A 
 
 
3 
(38) 
 
2 (66) 
 
2 (100) 
 
3 (100) 
 
 
 
0-25% 
13, 29 
 
 
DH  
 
5 (62) 
 
5 (100) 
 
0 (0) 
 
2 (40) 
 
 
D 
 
 
 
5 
(62) 
 
5 (100) 
 
1 (20) 
 
1 (20) 
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No Age 
(years) 
Sex Rockall 
score 
Blatchford 
score 
ATT Etiology Forrest 
classification 
Endoscopic 
treatment 
Initial 
hemostasis 
Rebleeding Outcome 
1 
81 M 10 7 Yes 
Duodenal 
ulcer 1b DH Yes 
no survived 30 
days 
2 
70 F 9 16 No 
Duodenal 
ulcer 1a DH 
No; 
embolized 
no survived 30 
days 
3 
84 M 10 16 Yes 
Duodenal 
ulcer 1a DH 
Yes no survived 30 
days 
4 
87 F 9 8 Yes 
Dual 
pathology 1b DH 
Yes no Non-GI 
bleed related 
death 
5 
55 M 5 10 No 
Duodenal 
ulcer 1a DH 
Yes no survived 30 
days 
6 
86 F 9 19 No 
Duodenal 
ulcer 
1a AH 
Yes Day 0;  too 
frail for 
treatment 
GI bleed 
death 
7 
71 F 8 15 Yes 
Duodenal 
ulcer 1a DH 
Yes 
no 
survived 30 
days 
8 
75 F 6 9 No 
Esophageal 
ulcer 1a AH 
Yes 
no 
survived 30 
days 
9 
52 F 8 15 No 
Esophageal 
ulcer 
1b DH 
Yes 
no 
Non-GI 
bleed related 
death 
10 
68 F 6 17 No 
Duodenal 
ulcer 1a DH 
Yes Yes; Day 6 - 
embolization 
survived 30 
days 
11 
64 M 8 9 Yes 
Esophageal 
ulcer 1b AH 
Yes 
no 
survived 30 
days 
12 74 M 8 14 Yes Duodenal 1b AH Yes no survived 30 
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F, Female; M, Male; ATT, Antithrombotic therapy; AH, adrenaline plus hemostatic spray; DH, conventional dual therapy plus hemostatic spray; GI, gastrointestinal 
 
Supplementary Table 1: Endoscopic treatment and outcomes of 20 consecutive patients with Forrest 1a and 1b ulcers treated with hemostatic spray from 
July 2013 to August 2015. 
ulcer days 
13 
56 M 5 13 Yes 
Duodenal 
ulcer 1a AH 
Yes 
no 
survived 30 
days 
14 
76 F 6 15 Yes 
Duodenal 
ulcer 1a AH 
Yes Yes; Day 0 - 
embolization 
survived 30 
days 
15 
76 F 6 17 No Gastric ulcer 1b DH 
Yes no survived 30 
days 
16 
27 M 4 10 No 
Duodenal 
ulcer 1a DH 
Yes no survived 30 
days 
17 
76 M 8 12 Yes 
Esophageal 
ulcer 1b AH 
Yes no survived 30 
days 
18 
75 M 8 14 No Ampullectomy 1a AH 
Yes no survived 30 
days 
19 
79 M 6 17 No Mallory-Weiss 1b DH 
Yes no survived 30 
days 
20 
66 F 8 14 Yes 
Duodenal 
ulcer 1a DH 
Yes no survived 30 
days 
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No Age 
(years) 
Sex Rockall 
score 
Blatchford 
score 
ATT Etiology Forrest 
classification 
Endoscopic 
treatment 
Initial hemostasis Rebleeding Outcome 
1 
73 F 9 16 yes Duodenal ulcer 1b A Yes 
Day 1; treated 
endoscopically 
GI bleed death 
2 
68 M 6 14 yes 
Duodenal ulcer 
1b AT 
Yes Day 6; treated 
endoscopically 
survived 30 days 
3 
84 M 7 12 yes 
Duodenal ulcer 
1b AC 
Yes 
no 
Non-GI bleed 
death 
4 
55 M 5 12 no 
Duodenal ulcer 
1a AC 
No – proceeded to 
laparotomy no 
survived 30 days 
5 86 F 9 20 yes Duodenal ulcer 1b AT Yes no survived 30 days 
6 
71 M 6 12 yes 
Duodenal ulcer 
1b A 
Yes Day 1; treated 
endoscopically 
Non-GI bleed 
death 
7 91 F 7 17 no Duodenal ulcer 1b A No no GI bleed death 
8 52 M 4 13 yes Duodenal ulcer 1b AT Yes no survived 30 days 
9 86 F 9 15 yes Gastric ulcer 1b AT Yes no survived 30 days 
10 
58 F 5 9 no 
Duodenal ulcer 
1a AT 
No – proceeded to 
laparotomy no 
survived 30 days 
11 74 M 6 10 yes Duodenal ulcer 1a AT Yes no survived 30 days 
12 64 F 8 12 no Sphincterotomy 1a AC Yes no survived 30 days 
13 72 F 4 14 no Duodenal ulcer 1a AC Yes no survived 30 days 
14 50 M 3 11 no Duodenal ulcer 1a AT Yes no survived 30 days 
15 
79 F 9 17 no 
Duodenal ulcer 
1a AC 
Yes Day 8; too frail for 
treatment 
GI bleed death 
16 71 F 6 13 no Duodenal ulcer 1a AT No – proceeded to no Non-GI bleed 
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F, Female; M, Male; ATT, Antithrombotic therapy; A, adrenaline only; AT, adrenaline plus a thermal device; AC, adrenaline plus hemostatic clip; GI, 
gastrointestinal 
 
Supplementary Table 2: Endoscopic treatment and outcomes of 20 consecutive patients with Forrest 1a and 1b ulcers from August 2010 to June 2013 before 
the introduction of hemostatic spray. 
laparotomy death 
17 89 M 9 16 yes Duodenal ulcer 1a AT Yes no survived 30 days 
18 62 M 8 16 yes Duodenal ulcer 1a AT Yes no survived 30 days 
19 91 M 7 14 yes Duodenal ulcer 1a AT Yes no survived 30 days 
20 
77 M 6 15 yes 
Duodenal ulcer 
1a AT 
Yes Day 2; treated 
endoscopically 
survived 30 days 
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No. of subjects Lesion Initial 
hemostasis 
(%) 
7-day re-
bleeding (%) 
30-day 
mortality (%) 
Reference 
10 Spurting vessel* 100 0 NA 19 
20 Forrest 1a and 1b 95 11 0 12 
7 Forrest 1a and 1b 100 14 NA 13 
16 Forrest 1a and 1b - 19 NA 11 
12 Forrest 1a and 1b 58 29± NA 25 
*In animal (pig) model; NVUGIB, nonvariceal upper gastrointestinal bleed; ±Unsustained primary 
hemostasis; NA, not available 
 
Supplementary Table 3: Previous studies on hemostatic spray as a monotherapy in high-
risk NVUGIB. 
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List of Acronynms 
 
 
AH   Adrenaline plus Hemospray® 
DH   Dual therapy plus Hemospray® 
Fr   French 
GI   Gastrointestinal 
IQR   Interquartile Range 
NHS   National Health Service 
NVUGIB  Non Variceal Upper Gastrointestinal Bleed 
  
 
 
